intellim Corporation
Celebrate the 15th anniversary

Accelerating Global Drug Development

We use cookies to ensure that we give you the best experience on our website. It will mean you have agreed with we would get cookies when you continue to see this website.


Our services will meet your needs
with high-quality and speed

intellim’s monitoring services

intellim works as a bridge between pharmaceutical companies and medical institutions, and provides high quality monitoring services with speed.

We provide full-services including site selection, IRB submission, CTA, IP distribution/collection, interim monitoring, CRF collection/review, SDV and close-out.
We can also support your global study(Global Development)

We can support you from Phase I throughout Phase IV study and PMS
We can support you from Phase I throughout Phase IV study and PMS

We can also support Investigator initiated study and generic drug development.

Our monitoring experiences

* High Quality Services
At recent GCP inspection, PMDA didn’t indicate any findings to 3 cases we supported.

* Speedy Operation and Services
In case of many studies which we supported recently, we achieved ahead of schedule.

Strength in Oncology

intellim implements "Oncology CRA Accreditation Program" which is based on our own training curriculum to cultivate Oncology Specialist. We offer those who can discuss trial design on equal terms with oncologist.

>>For more details

Multinational Study

We support you to conduct a multinational study in Asian region to take an advantage of less risk of ethnic difference. We can conduct a multinational study using the unified SOP with intellim Korea and QPS-Qualitix. We also can conduct a study using your SOP.

>>For more details

Network with our affiliate SMO

intellim and our affiliate SMOs (SEHMA Co., Ltd. and IBERICA Co., Ltd.) can support you to conduct a study at clinical pharmacology centers in Japan and abroad.

>>For more details

Subject Registration Center

As per our strict quality control standard, intellim reviews eligibility of subjects rapidly verifying with inclusion/exclusion criteria as per the protocol to obtain credible analyzable data.

>>For more details

For more information

If you have any comments, questions, please contact us.